All In Biotech

Drug Trial Radar · NCT06513949

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Jun 17, 2026

Primary completion

Mar 1, 2029

Study completion Jun 1, 2029

Sponsor

Lead sponsor
Implicit BioscienceIndustry
Sponsor type
Industry
Collaborators
University of Washington
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.

Conditions

  • Acute Respiratory Distress Syndrome
  • Adult Respiratory Distress Syndrome
  • Acute Lung Injury
  • Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Interventions

  • AtibuclimabBiological

    monoclonal antibody against human CD14

  • PlaceboOther

    Sterile normal saline for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Day 4 Oxygenation IndexTime frame: Day 1 through Day 4

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Harborview Medical Center

    Seattle, Washington · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.